0
0
Indian doctors are showing renewed confidence in prescribing oestrogen-based therapies for menopausal women as the United States Food and Drug Administration (USFDA) signals a possible removal of its longstanding black box warning—the strictest label reserved for drugs with severe or life-threatening risks—from menopause treatments containing oestrogen. This development is sparking fresh debate over hormone replacement therapy (HRT), a treatment once widely used for managing menopause symptoms but later linked to cancer and cardiovascular risks.
The USFDA’s black box warning was issued in 2003 after the Women’s Health Initiative (WHI) study found an increased risk of heart attack, stroke, and certain cancers in women using combined oestrogen-progestin therapy. However, an FDA panel recently indicated that local oestrogen therapies, such as vaginal creams, pose minimal systemic risk and should not carry the same warnings as systemic forms like oral pills or patches. The panel further suggested that previous studies may have overstated the risks associated with HRT.
These reassessments are influencing attitudes in India, where HRT is available primarily as pills and creams and is not accompanied by US-style black box warnings. Indian regulatory guidelines still echo international concerns, highlighting potential side effects including deep vein thrombosis, cancer, and dementia—especially in women with specific risk factors or those initiating therapy long after menopause. Nevertheless, leading clinicians now assert that updated scientific evidence favors the benefits of HRT for most healthy, symptomatic women, provided regular monitoring is conducted.
Dr. Archana Dwiwedi, chair of the mid-life committee of the Federation of Obstetric and Gynaecological Societies of India (FOGSI), commented that outdated risk perceptions had deprived many women of effective relief and called for a re-evaluation based on recent findings. Notably, the latest HRT regimens are considered safer, with the greatest benefits seen in women experiencing early menopause or at high risk of osteoporosis.
Despite this shift, less than five percent of India’s estimated 150 million postmenopausal women receive HRT. Younger clinicians tend to be more cautious, and patient hesitancy remains high, driven by residual fears of long-term risks. According to a 2025 national survey, more experienced doctors are likelier to endorse early initiation of HRT, while local therapies are favored for safer symptom control in select cases.
Experts highlight that while the FDA is considering label changes, robust scientific data and ongoing monitoring are essential. Local Indian guidelines may also evolve as global attitudes shift and newer HRT products demonstrate improved safety margins.
Disclaimer: This article is for informational purposes only and does not constitute medical advice. Patients should consult qualified healthcare professionals for personalized assessment and treatment decisions regarding hormone therapy and menopause management.
